In view of the complex issue of prolonging human life through gene editing technology, I propose the following systematic plans to be implemented in stages, integrating current scientific progress and ethical considerations.： 1. Targeting system of aging mechanism (MARS system) 1. Multi-target editing strategy： -DNA repair enhancement: CRISPRa mediates SIRT6 overexpression, combined with p53 gene editing to enhance genome monitoring capabilities -Telomere homeostasis: Use base editing technology to control the activation of TERC and TERT genes, and cooperate with p21 to activate to prevent cancer. -Mitochondrial optimization: Introduction of an engineering PGC-1a variant, combined with mito-Cas9 to remove heterogeneous mtDNA -Senescent cell clearance: Design a CRISPR-Cas9 switching system targeting p16INK4a to specifically remove senescent cells 2. Epigenetic reprogramming： -Develop a light-controlled OCT4/SOX2 nano particle system to achieve tissue-specific epigenetic reset -Precise editor for designing age-related methylation sites (AgeBE system) 2. Delivery system development 1. Smart nanocarriers： -CasMINI ribonucleoprotein complex wrapped in liposomes (size<30nm） -Tissue-targeted peptide modification (myocardial targeting CTP, brain targeting RVG29) -ROS responsive shell controls spatiotemporal specific release 2. Hematopoietic stem cell engineering： -Edit CD34+ stem cells in vitro to establish a "longevity stem cell bank" -Introduction of suicide gene (iCasp9) as a safety switch 3. Safety enhancement system 1. Gene circuit design： -Telomere length sensor (TLS) regulates TERT expression -Oxidative stress-responsive SOD2 activation loop -Two-factor authentication sgRNA system (activate true Cas9 after dCas9 verification) 2. Artificial intelligence monitoring platform： -Deep learning model predicts personalized off-target risks -Dynamic monitoring of clone evolution by single-cell sequencing -Organoid chip quickly evaluates organ-specific effects Fourth, the path of clinical transformation 1. Primate research stage (5-8 years)： -Verification of multi-gene synergy in crab-eating monkey model -Establish an aging biomarker scoring system (SenESCORE 2.0) -Construction of whole organ pathology atlas database 2. Human trial stage： -Phase I: Editing of hematopoietic system to treat progeria (n=10) -Phase II: Application of local tissue regeneration (skin/cornea, n=100) -Phase III: Systemic anti-aging treatment (healthy people aged 60-70, n=1000) V. Ethics-Social implementation framework 1. Life extension classification system： -Basic version (health span is extended to 100±5) -Enhanced version (health span 120±10, subject to approval by the ethics Committee) -Set the retirement age for gene therapy (GRA, set at 150 years old) 2. Global Aging Database： -Track the cross-generational effects of editing people in real time -Establish a credit system for the use of anti-aging technology -Develop an actuarial model of aging speed insurance This program innovatively integrates the concepts of synthetic biology and systematic medicine, and proposes to realize the dynamic balance of aging intervention through modular gene circuits. It focuses on breaking through the limitations of traditional single-gene editing and establishing an anti-aging network containing 23 core genes and 8 regulatory pathways. It is expected that through the three-stage implementation, the healthy life span can be gradually extended to the level of 120 years within 30 years, while reducing the incidence of aging-related diseases by 70%. It should be emphasized that the program needs to be accompanied by the establishment of a globally unified gene editing regulatory convention, and the development of supporting reverse editing technology as a safe withdrawal mechanism. It is recommended to establish the first international anti-aging research center in Dubai, use its special regulatory environment to accelerate technological transformation, and carry out continuous social adaptability research.